Plain English Summary
Background and study aims
Obstructive sleep apnoea (OSA) is a condition where there is repeated closing of the upper airway during sleep. It can cause snoring, waking during sleep and periods of not being able to breath. People who are obese with type 2 diabetes mellitus (T2DM) are at particularly high risk of developing OSA; approximately 86% have the condition. If not given effective treatment OSA can lead to long-term health issues. Current treatment options for OSA include losing weight (via either a very low energy diet, intensive lifestyle changes or metabolic surgery) or, in the absence of weight loss, a continuous positive airway pressure (CPAP) device that prevent the airway closing while the patient is asleep. However, compliance with these treatments are poor. Glucagonlike peptide receptor agonist (GLP1RA) therapy is commonly used in the treatment of diabetes. This drug has been shown to improve obesity and insulin resistance. To date, there have been no studies to examine the effects of GLP1RA on OSA in patients with T2DM. This study will examine the effectiveness of 26 weeks of GLP1RA, with and without CPAP, in obese patients with OSA and T2DM.
Who can participate?
Adults aged 18-75 with OSA and T2DM
What does the study involve?
Patients first have a series of physiological assessments to examine metabolic and cardiovascular (for example heart) health. They are then randomly allocated into one of 4 groups and treated accordingly: control (no treatment), GLP1RA, CPAP, and finally GLP1RA and CPAP. All assessments are repeated after the study period of 26 weeks.
What are the possible benefits and risks of participating?
Not provided at time of registration.
Where is the study run from?
GP and outpatients clinics across the Liverpool and Newcastle areas (UK)
When is the study starting and how long is it expected to run for?
September 2015 to October 2017
Who is funding the study?
Novo Nordisk UK Research Foundation
Who is the main contact?
Ms Julie Perry
A randomised, controlled multi-centre trial of 26 weeks of subcutaneous liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA)
The aim of this study is to examine the efficacy of 26 weeks of glucagon-like peptide receptor agonist (GLP1RA) therapy , with and without continuous positive airway pressure (CPAP) treatment in obese patients with obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM).
Randomised; Interventional; Design type: Treatment
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Diabetes, sleep apnoea
Following screening, patients with OSA and T2DM will be recruited from primary (GPs) and secondary care settings (outpatients clinics) across the Liverpool and Newcastle areas. After informed consent has been obtained patients will undergo a series of physiological assessments to examine metabolic and cardiovascular health and will then randomised to one of the following interventions:
1. Control (no intervention)
4. GLP1RA & CPAP
All assessments will be repeated following the intervention period.
Primary outcome measure
Secondary outcome measures
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Males or females, age 18-75 years.
2. Reproductive Status: Definition of Women of Child Bearing Potential (WOCBP). WOCBP comprises women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who are not postmenopausal (see definition below)
3. WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent units of HCG) within 0 to 72 hours before the first dose of study drug.
4. A clinical diagnosis of type 2 diabetes
5. Glycosylated haemoglobin (HbA1c) >53mmol/mol
6. BMI>30kg/ m2
7. Currently treated with either diet or any combination of metformin and sulphonylureas (excluding patients treated with DPPIV inhibitors*, pioglitazone or insulin)
8. No current use of Liraglutide treatment
9. Patients with moderatesevere OSA as assessed by polysomnographic criteria, either by:
9.1. Apnoeahypopnea index (AHI) >15 events/hour) with overnight domiciliary multichannel sleep study (ResMed, Apnoea Link™ or other suitable alternative)
9.2. Overnight desaturation index (pulse oximetry): ODI>10 (4% dip in oxygen saturation more than 10 events/hour)
9.3. Currently symptomatic for OSA, with excessive daytime sleepiness
*Patients who are currently treated with DPPIV inhibitors can be included providing the treatment is discontinued before baseline tests.
Target number of participants
Planned Sample Size: 152; UK Sample Size: 152
Participant exclusion criteria
1. Medical History and Concurrent Diseases
2. Females of childbearing age who are not using adequate contraceptive methods or who are planning a pregnancy in the next 6 months
3. Treatment with DPP-IV inhibitors, pioglitazone or subcutaneous insulin injections or with the antiobesity medication, orlistat
4. Patients in whom there may be occupational implications to a diagnosis of OSA e.g. professional drivers or operating machinery
5. Type 1 diabetes mellitus
6. Congestive heart failure class IIIIV
7. Renal impairment: eGFR less than 30 ml/minute/1.73m2
8. Previous history of acute pancreatitis
10. Hypothyroidism (subjects with a normal TSH and free T4, and on a stable dose of thyroxine for at least 3 months may be included)
11. Uncontrolled hypertension (blood pressure >170/120 mmHg)
12. Recent (< 6 months) myocardial infarction
13. Previous stroke (with residual neurological deficit)
14. Significant cardiac dysrhythmias (including pacemaker or ICD)
15. Presence of any other medical condition that would, in the opinion of the investigator or their clinician preclude safe participation in the study. This decision should be informed by Liraglutide precautions for use statements which will be provided to all clinicians and the research team
16. Alcohol consumption in excess of daily recommended limits (21 units/week females, 28 units/week males)
17. Any history of internal metal, pacemakers, or ferromagnetic metallic implants intraocular foreign bodies or cerebral aneurysm clips (exclusion from MR scanning)
18. History of seizures or unexplained syncope
19. Severe sleepiness
20. Weight <140kg (due to limitations of MRI scanner)
21. Subjects with a history of any serious hypersensitivity reaction to GLP1RA
22. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the study duration plus 8 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized
23. Women who are pregnant or breastfeeding
24. Diabetes treated with pioglitazone, GLP1 analogues or insulin
25. Use of other weight loss medication or any drug that might affect body weight or appetite (including antidepressants, antipsychotics, corticosteroids)
26. Prisoners or subjects who are involuntarily incarcerated
27. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Cancer Research UK
Liverpool CR-UK Centre - Waterhouse Building 1-3 Brownlow Street
Novo Nordisk UK Research Foundation
Funding Body Type
private sector organisation
Funding Body Subtype
Trusts, charities, foundations (both publically funded and privately funded)
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)